Ensign Peak Advisors’s NewAmsterdam Pharma Warrant NAMSW Stock Holding History

Ensign Peak Advisors’s Portfolio NAMSW Stock Details NAMSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-150,000	Closed	-$470K	–	1742
2023 Q4	$470K	Hold	150,000	–	–	﹤0.01%	1667
2023 Q3	$255K	Hold	150,000	–	–	﹤0.01%	1711
2023 Q2	$314K	Hold	150,000	–	–	﹤0.01%	1709
2023 Q1	$278K	Hold	150,000	–	–	﹤0.01%	1721
2022 Q4	$120K	Buy	+150,000	New	+$123K	﹤0.01%	1763

Other funds holding NAMSW

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return

Ensign Peak Advisors's NAMSW Position: Q1 2024 in Review

Ensign Peak Advisors sold out of NewAmsterdam Pharma Warrant (NAMSW) in Q1 2024, closing a stake of 150,000 shares — an estimated $470K sold.

Ensign Peak Advisors first reported a position in NAMSW in Q4 2022 and held it in 5 quarters. The position peaked at $470K in Q4 2023. 11 funds tracked by Wall St. Rank hold NAMSW as of Q1 2024.

Ensign Peak Advisors reported no remaining NewAmsterdam Pharma Warrant position as of Q1 2024 after selling out during the quarter.
Ensign Peak Advisors sold 150,000 NewAmsterdam Pharma Warrant shares in Q1 2024, an estimated $470K.
Ensign Peak Advisors first reported a position in NewAmsterdam Pharma Warrant in Q4 2022 and held it in 5 quarters.
Ensign Peak Advisors's NewAmsterdam Pharma Warrant position peaked at $470K in Q4 2023.
11 funds tracked by Wall St. Rank held NewAmsterdam Pharma Warrant as of Q1 2024.

Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.